South Korea

BMI View: The fourth quarter of 2012 brought positive revenue growth for large domestic pharmaceutical firms in South Korea, the first positive result after many erratic price had been... 2013-03-07

BMI View: Merck & Co's collaboration with Samsung Bioepis on biosimilars highlights its confidence in South Korea's biotechnology capabilities. This is the second collaboration... 2013-02-22

BMI View: Although medicine prices have remained stable for now, the South Korean pharmaceutical market remains in a state of uncertainty as companies recorded negative financial growth... 2012-11-19

BMI View: The halting of biosimilars trials by Samsung and Teva Pharmaceutical Industries highlights the challenges in the development of biosimilars, which are fundamentally complex... 2012-10-19

BMI View: South Korea will continue to be a leading country in Asia in terms of biosimilars development, as well as in general biotechnology research and development (R&D),... 2012-08-01

BMI View: South Korean pharmaceutical companies will continue to be negatively affected by the government's medicine price-cut policies. We believe the continued poor performance expected... 2012-07-25

BMI View: The liberalisation of South Korea's over-the-counter (OTC) medicines sector will continue to proceed at a sluggish pace as government takes into account the interests of various... 2012-07-16